In principle AMPs could be combined with (i) conventional tuberculosis drugs in accordance with drug susceptibility testing, (ii) adjuvants which promote effector mechanisms of macrophages, or (iii) molecules that optimize the targeting of AMPs to the site of infection. This evidence concerns the gene ADSL and tuberculosis.